SRZNW
Price:
$0.0299
Market Cap:
$39.78M
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to part...[Read more]
Industry
Biotechnology
IPO Date
2021-08-10
Stock Exchange
NASDAQ
Ticker
SRZNW
According to Surrozen, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.01. This represents a change of -99.51% compared to the average of -2.05 of the last 4 quarters.
The mean historical PE Ratio of Surrozen, Inc. over the last ten years is -2.32. The current -0.01 PE Ratio has changed -56.95% with respect to the historical average. Over the past ten years (40 quarters), SRZNW's PE Ratio was at its highest in in the December 2022 quarter at 0.60. The PE Ratio was at its lowest in in the March 2022 quarter at -280.88.
Average
-2.32
Median
-2.45
Minimum
-4.30
Maximum
-0.44
Discovering the peaks and valleys of Surrozen, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 51.05%
Maximum Annual PE Ratio = -0.44
Minimum Annual Increase = -83.01%
Minimum Annual PE Ratio = -4.30
Year | PE Ratio | Change |
---|---|---|
2023 | -0.44 | -39.65% |
2022 | -0.73 | -83.01% |
2021 | -4.30 | 16.19% |
2020 | -3.70 | 51.05% |
The current PE Ratio of Surrozen, Inc. (SRZNW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.82
5-year avg
-2.32
10-year avg
-2.32
Surrozen, Inc.’s PE Ratio is greater than Surrozen, Inc. (-0.89), greater than Celularity Inc. (-1.43), greater than Quantum-Si incorporated (-2.06), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Humacyte, Inc. (-3.52),
Company | PE Ratio | Market cap |
---|---|---|
-0.89 | $39.78M | |
-1.43 | $52.39M | |
-2.06 | $166.64M | |
-0.00 | $2.82K | |
-3.52 | $238.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Surrozen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Surrozen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Surrozen, Inc.'s PE Ratio?
How is the PE Ratio calculated for Surrozen, Inc. (SRZNW)?
What is the highest PE Ratio for Surrozen, Inc. (SRZNW)?
What is the 3-year average PE Ratio for Surrozen, Inc. (SRZNW)?
What is the 5-year average PE Ratio for Surrozen, Inc. (SRZNW)?
How does the current PE Ratio for Surrozen, Inc. (SRZNW) compare to its historical average?